Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.
Ondine Biomedical Inc. announced a health economic study by the York Health Economics Consortium, which highlights the cost-saving benefits of Steriwave nasal decolonization in reducing surgical site infections. The study suggests that using Steriwave before major surgeries could save UK hospitals up to £200 million annually, with significant savings across various surgical categories. This analysis supports the adoption of Steriwave as a cost-effective, non-antibiotic infection prevention method, potentially improving patient outcomes and reducing hospital stays.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, including the Steriwave nasal photodisinfection system, which is approved in Europe, Canada, and other countries. Ondine is also developing therapies for conditions such as chronic sinusitis and ventilator-associated pneumonia.
YTD Price Performance: 2.86%
Average Trading Volume: 271,719
Technical Sentiment Signal: Strong Buy
Current Market Cap: £38.78M
For a thorough assessment of OBI stock, go to TipRanks’ Stock Analysis page.